-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: iHuPDX Platform Features and Advantages
Author:
InnoModels
Release time:
2024-06-24
In the field of cancer treatment, finding efficient and accurate treatment solutions has always been the common pursuit of researchers and doctors. With the rapid development of biotechnology, InnoModels Biotechnology has injected new vitality into the development of individualized precision medicine with its unique iHuPDX platform. In this article, we will introduce the features and advantages of the iHuPDX platform of InnoModels Biotechnology in detail, in order to provide readers with a more comprehensive understanding.
Platform features:
1. Personalized Tumor Models
The core technology of the iHuPDX platform of InnoModels Biotechnology lies in its ability to form individualized tumor models that are highly close to the actual situation of patients based on the xenotransplantation technology of individual tumor cells of patients. This technology collects cancer tissue samples from patients and transplants them into animals such as mice to form individualized transplanted tumors. Compared with traditional tumor models based on standardized cell lines or tissue samples, the iHuPDX platform can more accurately simulate the growth, metastasis, and drug response of the patient's tumor, providing strong support for precision medicine.
2. High accuracy
Since the iHuPDX platform is directly derived from patients' tumor cells, it can more accurately simulate the characteristics of patients' tumors. This allows researchers to test the response of different drugs to a specific patient's tumor on the model and predict the efficacy and possible side effects of the drug in the patient. This predictive ability allows physicians to select the most appropriate drug combination and dosage for a patient before treatment, increasing the success rate of treatment and reducing unnecessary risks.
3. Stable and Reliable
With advanced primary cell inoculation technology, the iHuPDX platform is able to achieve early and uniform growth, ensuring that efficacy experiments are conducted within the optimal window. At the same time, the homogenization of the same batch of samples is guaranteed through the cell suspension modeling approach, resulting in a high degree of consistency in the growth rate and biological characteristics of the model. This stability not only ensures the reliability of the experimental results, but also reduces the experimental and time costs.

Platform Advantages:
1. Leading the new trend of individualized precision medicine
The iHuPDX platform of InnoModels Biotechnology is leading the new trend of individualized precision medicine with its unique individualized tumor model technology. In the field of cancer treatment, individualized treatment plans have become an inevitable trend for future development. The iHuPDX platform is a powerful promoter of this trend, providing cancer patients with more accurate and effective treatment options.
2. Promoting tumor immunotherapy research
In addition to supporting individualized precision medicine, the iHuPDX platform also demonstrates significant advantages in tumor immunotherapy research. By combining the iHuPDX platform with a humanized model of the PBMC immune system, researchers can simulate the interactions between tumors and the immune system, gain a deeper understanding of the immune mechanisms of tumors, and develop new immunotherapies. This combination enables the iHuPDX platform to have a wide range of applications in the field of tumor immunotherapy.
3. Improving the efficiency of new drug development
The iHuPDX platform of InnoModels Biotechnology provides strong support for new drug development with its high-throughput generic clinical research platform. With the help of this platform, researchers can conduct high-throughput clinic-like efficacy testing of drugs at an early stage, so as to quickly screen out potential drug candidates. This highly efficient R&D process not only reduces the cost and time of new drug development, but also improves the success rate of R&D.
In conclusion, with its unique individualized tumor modeling technology and significant advantages, the iHuPDX platform of InnoModels Biotechnology shows a broad application prospect in the field of individualized precision medicine and tumor immunotherapy research. In the future, with the continuous development and improvement of this technology, we believe that it will play an even more important role in the field of cancer treatment and bring hope and gospel to more patients.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd